Kyung Wook Shin1, Sukki Cho2, Jin-Haeng Chung3, Kyung Won Lee4, Choon-Taek Lee5, Kwhanmien Kim6, Sanghoon Jheon6. 1. Department of Thoracic and Cardiovascular Surgery, Seoul National University Bundang Hospital, Gumi-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, Republic of Korea. 2. Department of Thoracic and Cardiovascular Surgery, Seoul National University Bundang Hospital, Gumi-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, Republic of Korea; Department of Thoracic and Cardiovascular Surgery, Seoul National University College of Medicine, Seoul, Republic of Korea. Electronic address: skcho@snubh.org. 3. Department of Pathology, Seoul National University Bundang Hospital, Gumi-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, Republic of Korea; Department of Pathology, Seoul National University College of Medicine, Seoul, Republic of Korea. 4. Department of Radiology, Seoul National University Bundang Hospital, Gumi-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, Republic of Korea; Department of Radiology, Seoul National University College of Medicine, Seoul, Republic of Korea. 5. Department of Internal Medicine, Seoul National University Bundang Hospital, Gumi-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, Republic of Korea; Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea. 6. Department of Thoracic and Cardiovascular Surgery, Seoul National University Bundang Hospital, Gumi-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, Republic of Korea; Department of Thoracic and Cardiovascular Surgery, Seoul National University College of Medicine, Seoul, Republic of Korea.
Abstract
BACKGROUND: Our study compared the prognosis of solid node-negative adenocarcinoma sized less than 20 mm with that of part-solid node-negative adenocarcinoma with an invasive tumor size of less than 20 mm. METHODS: From 2003 to 2012, 191 patients were selected with a diagnosis of solid or part-solid pathologic node-negative adenocarcinoma with an invasive component sized less than 20 mm. The enrolled patients were categorized into two groups: group 1 had solid adenocarcinoma consisting only of the invasive component, and group 2 had part-solid adenocarcinoma consisting of both an in situ and an invasive component. Recurrence-free survival and overall survival at 5 years were compared using Kaplan- Meier survival analysis and the log-rank test. RESULTS: The mean size of the invasive component was 15.9 mm in group 1 (n = 92) and 15.2 mm in group 2 (n = 99; p = 0.06), and the mean total lesion size was 15.9 mm in group 1 and 21.0 mm in group 2 (p < 0.001). The median follow-up duration was 54.2 months. The 5-year overall survival rates were 90.3% in group 1 and 93.8% in group 2 (p = 0.160), and the recurrence-free survival rates were 84.0% in group 1 and 93.7% in group 2 (p = 0.037). Lymphovascular invasion and high maximum standardized uptake values were significantly more common in group 1. CONCLUSIONS: Although the total size of the part-solid adenocarcinoma lesions was larger than that of the solid adenocarcinoma lesions, the prognosis of part-solid adenocarcinoma was better than that of solid adenocarcinoma in cases of node-negative adenocarcinoma with invasive components sized less than 20 mm.
BACKGROUND: Our study compared the prognosis of solid node-negative adenocarcinoma sized less than 20 mm with that of part-solid node-negative adenocarcinoma with an invasive tumor size of less than 20 mm. METHODS: From 2003 to 2012, 191 patients were selected with a diagnosis of solid or part-solid pathologic node-negative adenocarcinoma with an invasive component sized less than 20 mm. The enrolled patients were categorized into two groups: group 1 had solid adenocarcinoma consisting only of the invasive component, and group 2 had part-solid adenocarcinoma consisting of both an in situ and an invasive component. Recurrence-free survival and overall survival at 5 years were compared using Kaplan- Meier survival analysis and the log-rank test. RESULTS: The mean size of the invasive component was 15.9 mm in group 1 (n = 92) and 15.2 mm in group 2 (n = 99; p = 0.06), and the mean total lesion size was 15.9 mm in group 1 and 21.0 mm in group 2 (p < 0.001). The median follow-up duration was 54.2 months. The 5-year overall survival rates were 90.3% in group 1 and 93.8% in group 2 (p = 0.160), and the recurrence-free survival rates were 84.0% in group 1 and 93.7% in group 2 (p = 0.037). Lymphovascular invasion and high maximum standardized uptake values were significantly more common in group 1. CONCLUSIONS: Although the total size of the part-solid adenocarcinoma lesions was larger than that of the solid adenocarcinoma lesions, the prognosis of part-solid adenocarcinoma was better than that of solid adenocarcinoma in cases of node-negative adenocarcinoma with invasive components sized less than 20 mm.